Company
Nevro
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
3
510(k), De Novo and PMA
Device trials
10
As lead sponsor, any status
Adverse event reports
680
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$58.6M
1 Form D offering, 2011 to 2011
Equity
$58.6M
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: equity, $58.6M raised of $58.6M sought, first sale Jul 15, 2011, 13 investors.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| Jul 15, 2011 | Equity | $58.6M | $58.6M | 13 | Rule 506 | Form D ↗Jul 28, 2011 |
Company details
From the company's latest Form D.
- Legal name
- NEVRO CORP
- Headquarters
- Menlo Park, California
- Incorporated
- Delaware in 2006
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1444380 ↗
Executives, directors and promoters
As listed on the latest Form D.
10 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Nevro.
Latest FDA decisions
- Senza Spinal Cord Stimulation (SCS) SystemPMA supplement
P130022-S042 · Decided Jan 18, 2022 · 180 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
- Senza Spinal Cord Stimulation (SCS) SystemPMA supplement
P130022-S039 · Decided Jul 16, 2021 · 200 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
P130022 · Decided May 8, 2015 · 583 days after receipt
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb PainPivotal-lookingCompleted
NCT03228420 · 430 participants · Start Jul 20, 2017 · Primary completion May 1, 2020
Device: Senza HF10 Therapy · For: Painful Diabetic Neuropathy
Sites: Bradenton, Florida; Stockbridge, Georgia; Durham, North Carolina · 4 sites in all
- Pain and Neurological Function Improvements With 10 kHz Spinal Cord Stimulation Treatment of Painful Diabetic NeuropathyPivotal-lookingActive, not recruiting
NCT05777317 · 143 participants · Start Apr 24, 2023 · Primary completion Mar 13, 2026
Device: 10 kHz SCS · For: Painful Diabetic Neuropathy
Sites: Winston-Salem, North Carolina; Medford, Oregon
- Clinical Trial of MED HF10™ Spinal Cord Stimulation for the Treatment of Chronic PainActive, not recruiting
NCT06897280 · 25 participants (planned) · Start Nov 16, 2021 · Primary completion Nov 16, 2024
Device: SCS Device Program Setting · For: Chronic, Intractable Back Pain and/or Leg Pain
Sites: Overland Park, Kansas
7 more trials with a free account
Reports received
680
Received Nov 1, 2025 to Nov 20, 2026. Includes 3 of another or unstated type.
Malfunction reports
24
3.5% of reports
Injury reports
650
96% of reports
Death reports
3
0.4% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 5 | 46 | 13 | 0 |
| Jan 24 | 1 | 56 | 17 | 1 |
| Feb 24 | 8 | 90 | 19 | 0 |
| Mar 24 | 3 | 64 | 28 | 0 |
| Apr 24 | 4 | 69 | 16 | 0 |
| May 24 | 2 | 86 | 20 | 0 |
| Jun 24 | 3 | 90 | 30 | 0 |
| Jul 24 | 2 | 78 | 31 | 0 |
| Aug 24 | 3 | 80 | 31 | 0 |
| Sep 24 | 0 | 80 | 13 | 0 |
| Oct 24 | 2 | 90 | 0 | 0 |
| Nov 24 | 8 | 83 | 0 | 0 |
| Dec 24 | 1 | 67 | 0 | 0 |
| Jan 25 | 2 | 119 | 0 | 0 |
| Feb 25 | 0 | 74 | 0 | 0 |
| Mar 25 | 3 | 78 | 0 | 0 |
| Apr 25 | 4 | 84 | 2 | 0 |
| May 25 | 3 | 74 | 2 | 0 |
| Jun 25 | 3 | 88 | 0 | 0 |
| Jul 25 | 4 | 55 | 0 | 0 |
| Aug 25 | 0 | 61 | 0 | 0 |
| Sep 25 | 2 | 76 | 2 | 0 |
| Oct 25 | 0 | 106 | 1 | 0 |
| Nov 25 | 3 | 71 | 0 | 0 |
| Dec 25 | 0 | 61 | 1 | 0 |
| Jan 26 | 1 | 40 | 0 | 0 |
| Feb 26 | 2 | 41 | 0 | 0 |
| Mar 26 | 4 | 57 | 1 | 0 |
| Apr 26 | 2 | 74 | 0 | 0 |
| May 26 | 4 | 55 | 0 | 1 |
| Jun 26 | 6 | 45 | 0 | 0 |
| Jul 26 | 1 | 45 | 0 | 0 |
| Aug 26 | 1 | 55 | 0 | 2 |
| Sep 26 | 0 | 56 | 0 | 0 |
| Oct 26 | 0 | 50 | 1 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
- SENZA637
7 more in this ranking with a free account
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.